Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

710528.pdf (1.11 MB)

Document type

Article

Version

Published version

Publication date

2020-12-08

Publication license

cc-by (c) Bragado, Paloma et al., 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/175915

Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.18632/oncotarget.27829

Abstract

The majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].

Subject

Fibroblasts, Càncer

Subject (English)

Fibroblasts, Cancer

Citation

Collections

Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Citation

BRAGADO, Paloma, et al. Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression. Oncotarget. 2020. Vol. 11, num. 49, pags. 4541-4543. ISSN 1949-2553. [consulted: 18 of August of 2026]. Available at: https://hdl.handle.net/2445/175915

Export metadata

JSON - METS

Share record